.Attribute Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research, after a typical consequence of 11 months, people with metastatic gastrointestinal lumps who received biomarker-matched treatments based upon distributing tumor DNA profiling showed a better scientific advantage than those receiving incomparable therapy.